By 2030, the market is set to reach $33.26 billion, maintaining a CAGR of 8.6%
Your prescriber can decide whether to taper, stop, start, or overlap medicines based on your full regimen
It just reveals where real-world data actually lives
For these reasons, Billings called fixed ratio combinations the ideal therapy if you are trying to limit side effects of nausea and vomiting. Starting a GLP-1 tends to cause more nausea and vomiting in the first few weeks
Fewer events in the placebo arm of SURMOUNT-1 compared with ONeil, STEP 1 and STEP 8 for total gastrointestinal AEs and nausea AEs suggest that the relative safety of tirzepatide versus liraglutide and semaglutide may be underestimated for these outcomes (see Supplementary Material Table S3)
[PubMed] [Google Scholar] 8.Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S